Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696877 · ClinicalTrials.gov registry record · Phase 1
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
A Phase 1 study of Prostate Cancer Adenocarcinoma in Situ, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01696877 is a Phase 1 study of Prostate Cancer Adenocarcinoma in Situ that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01696877, a Phase 1 study of Prostate Cancer Adenocarcinoma in Situ, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to remove their cancerous prostate glands who have also received standard hormonal therapy.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG GVAX
- DRUG degarelix acetate
Study Locations (1)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-01-18 |
| Est. Completion | 2018-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696877
The ClinicalTrials.gov registry entry for NCT01696877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer Adenocarcinoma in Situ appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01696877 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01696877 about?
NCT01696877 is a clinical study titled "A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer". This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to remove their cancerous prostate glands who have also received standard...
What is the current status of trial NCT01696877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-01-18. Estimated completion is 2018-12-18.
What conditions does trial NCT01696877 study?
This clinical trial studies the following conditions: Prostate Cancer Adenocarcinoma in Situ.
What interventions are being tested in trial NCT01696877?
The interventions under investigation include: Cyclophosphamide (DRUG), GVAX (DRUG), degarelix acetate (DRUG).
Who is sponsoring clinical trial NCT01696877?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01696877 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.